Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine (S11.004)

Authors

Institutions

Publication Details

Journal
Neurology
Published
2025-04-07
DOI
https://doi.org/10.1212/wnl.0000000000211307
Citations
1
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
1.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine (S11.004)

Christopher Jensen, Irfan Qureshi, Joris Vriens, Andrew T. Lucas et al.
1 citations
Neurology
Migraine and Headache Studies
1.47
article

Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine (S11.004)

Christopher Jensen, Irfan Qureshi, Joris Vriens, Andrew T. Lucas, Richard Bertz, Thomas Voets, Mary Donohue, Patricia K. Mydlow, Beth Emerson, Vladimir Coric, Eric Ashbrenner, Volkan Granit
article en
1 citations

Abstract

No abstract available for this paper.
NeurologyVol. 104(7_Supplement_1)
Ludlow Community Hospital (GB), Biohaven Pharmaceuticals (United States) (US), VIB-KU Leuven Center for Brain & Disease Research (BE), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 21%
Migraine and Headache Studies
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.